Clinical Trial Goal
To find out if pemigatinib is safe and works well to treat MCL, MZL, NMZL or SMZL that has relapsed or is refractory
You may be able to join this trial if you:
- Are 18 years old or older
- Have one of the following that has relapsed or is refractory:
- MCL
- MZL
- NMZL
- SMZL
- Do not have lymphoma in your brain or spinal cord
- Have not been treated with a drug that targets FGFR. Your doctor can tell you this
- Have not had autologous (your own cells) blood or marrow transplant (BMT) in the last 3 months
- Have not had CAR T-cell therapy in the last 1 month
- Agree to have other standard tests done to see if you can be in the clinical trial
Trial Details
Pemigatinib is a small molecule inhibitor that targets FGFR on certain cells.
You’ll get treatment in cycles that last 1 month. In each cycle, you'll get:
You’ll get treatment in cycles that last 1 month. In each cycle, you'll get:
- Pemigatinib – A pill that you take by mouth 1 time each day
You'll have scans to see how well the treatment is working. The clinical trial doctors will check your health for up to 4 years.
The Food and Drug Administration (FDA) has approved pemigatinib to treat bile duct cancer. Using it in this way to treat MCL, MZL, NMZL or SMZL that has relapsed or is refractory is new and unproven.
Contacts
Rachel Kingsford, 801-585-0115, rachel.kingsford@hci.utah.edu
Narendranath Epperla, MD, MS, 8015850255, naren.epperla@hci.utah.edu
Locations
Huntsman Cancer Institute at University of UtahRECRUITING
Salt Lake City, Utah
Contacts:
- Rachel Kingsford
Sponsors
collaborator: Incyte Corporation, lead: University of Utah
